AnaptysBio Financial Statements
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AnaptysBio revenue and earnings
In fiscal 2025, AnaptysBio generated $234.6 million in revenue, up 157.0% from fiscal 2024, its 3rd consecutive year of revenue growth. AnaptysBio reported a net loss of $13.2 million, compared with a loss of $145.2 million a year earlier. Operating margin was 96.7%.
Diluted earnings per share came in at -$0.44. Over the last 5 fiscal years, ANAB's revenue has grown at a 25.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
AnaptysBio income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M | 75.00M | 8.00M | 5.00M | 10.00M | 16.68M |
| Revenue growth (YoY) | +157.01% | +432.03% | +66.78% | -83.72% | -15.77% | +837.50% | +60.00% | -50.00% | -40.06% | -5.05% |
| Operating Expenses | 7.70M | 25.13M | 181.57M | 125.44M | 119.99M | 98.88M | 115.43M | 71.72M | 38.78M | 19.71M |
| Research & Development | 135.97M | 163.84M | 132.28M | 88.80M | 98.50M | 80.03M | 99.34M | 56.20M | 29.44M | 15.42M |
| Operating Income | 226.90M | 66.15M | -164.41M | -115.15M | -56.81M | -23.88M | -107.43M | -66.72M | -28.78M | -3.02M |
| Interest Expense | — | — | — | — | 0 | 0 | 1.04M | 1.65M | 1.77M | 458.00K |
| Other Income (Expense) | -64.63M | -35.01M | 788.00K | -13.55M | -982.00K | 3.95M | 9.94M | 4.87M | -1.29M | -1.23M |
| Pretax Income | 162.28M | 31.14M | -163.62M | -128.70M | -57.80M | -19.93M | -97.49M | -61.85M | -30.07M | -4.26M |
| Income Tax | 772.00K | 158.00K | -4.00K | 24.00K | 0 | 0 | -152.00K | -192.00K | 0 | 0 |
| Net Income | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M | -19.93M | -97.34M | -61.66M | -30.07M | -4.26M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -1.62 |
| EPS (Diluted) | -0.44 | -4.92 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -1.62 |
| Shares Outstanding (Basic) | 28.76M | 28.38M | 26.92M | 28.16M | 27.43M | 27.30M | 27.06M | 24.67M | 19.78M | 2.64M |
| Shares Outstanding (Diluted) | 30.23M | 29.54M | 26.92M | 28.16M | 27.43M | 27.30M | 27.06M | 24.67M | 19.78M | 2.64M |
| EBITDA | 226.92M | 66.17M | -163.76M | -114.48M | -56.20M | -23.32M | -106.92M | -66.41M | -28.60M | -2.79M |
| Operating Margin | 96.72% | 72.47% | -958.27% | -1119.41% | -89.93% | -31.84% | -1342.90% | -1334.44% | -287.81% | -18.13% |
| Net Margin | -5.64% | -159.10% | -953.66% | -1251.33% | -91.49% | -26.57% | -1216.70% | -1233.12% | -300.70% | -25.53% |
This table shows 10 annual periods of AnaptysBio's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ANAB's reporting calendar. What is a income statement?